Trial resultsJun 8, 2026141 days ago
Phase 3 KEYNOTE-D46/EVOKE-03 discontinued after PFS missed significance
Merck & reported results from its Phase 3 study of Trodelvy (sacituzumab govitecan) + KEYTRUDA for First-line PD-L1 TPS >=50% metastatic NSCLC on Jun 8, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsClinical trial results · also called: readout / topline data
- Company
- Merck & Co., Inc. MRK
- Drug
- Trodelvy (sacituzumab govitecan) + KEYTRUDA
- For
- First-line PD-L1 TPS >=50% metastatic NSCLC
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Jun 8, 2026
- Source note
- Merck and Gilead halted the study of Trodelvy plus KEYTRUDA versus KEYTRUDA alone in previously untreated PD-L1-high metastatic NSCLC on DMC recommendation; the PFS improvement was numerical but not statistically significant.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: merck.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- MRK headlines on this site
Merck & Co., Inc.
1 upcoming · 13 past catalysts
More from MRK
Merck & expects to report results from its Phase 3 study of sacituzumab tirumotecan (MK-2870) for Advanced/recurrent endometrial cancer (TroFuse-005) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Sac-TMT TroFuse-005 endometrial cancer detailed Ph3 data presentation · Clinical trial results (readout / topline data)
- Drug
- sacituzumab tirumotecan (MK-2870)
- For
- Advanced/recurrent endometrial cancer (TroFuse-005)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Merck Aug 4, 2026 Q2 earnings slides list this under milestones 'expected over next six months' (Aug 2026-Jan 2027); no congress named, so H2 2026 is an approximation of that window. Topline (OS and PFS met) was announced in Q2 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: merck.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- MRK headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page